Factor VIII inhibitor and source of replacement therapy.
作者信息
Mannucci Pier Mannuccio, Gringeri Alessandro, Santagostino Elena, Peyvandi Flora
出版信息
Blood Transfus. 2012 Jan;10(1):112-3. doi: 10.2450/2011.0064-11. Epub 2011 Sep 21.
Abstract
摘要
相似文献
1
Factor VIII inhibitor and source of replacement therapy.凝血因子 VIII 抑制剂及替代疗法的来源。
Blood Transfus. 2012 Jan;10(1):112-3. doi: 10.2450/2011.0064-11. Epub 2011 Sep 21.
2
Clinical and organisational aspects of haemophilia care: the patients' view.血友病护理的临床与组织方面：患者视角
Blood Transfus. 2012 Jan;10(1):110-1. doi: 10.2450/2011.0043-11. Epub 2011 Sep 21.
3
Blood safety and the choice of anti-hemophilic factor concentrate.
Pediatr Blood Cancer. 2007 Jan;48(1):117. doi: 10.1002/pbc.21086.
4
[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].[病毒灭活的凝血因子VIII和IX浓缩物在血友病治疗中的病毒安全性现状]
Infusionsther Transfusionsmed. 1994 Aug;21 Suppl 1:80-3.
5
[Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].[甲型血友病治疗中的安全性。FVIII:C 浓缩剂的病毒灭活]
Acta Med Port. 1992 Dec;5(11):587-90.
6
Parvovirus B19 and blood products.细小病毒B19与血液制品
Lancet. 1994 Apr 30;343(8905):1101.
7
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
Lancet. 1997 Dec 6;350(9092):1704. doi: 10.1016/s0140-6736(05)64307-3.
8
Parvovirus B19 and blood products.细小病毒B19与血液制品
Lancet. 1994 Apr 30;343(8905):1101.
9
Transfusion. Argentina courts to try HIV-blood contamination cases.输血。阿根廷法院将审理艾滋病毒血液污染案件。
AIDS Policy Law. 2008 May;23(6):8.
10
Successful preoperative apheresis of factor VIII antibody using factor VIII concentrate as a replacement fluid.使用凝血因子 VIII 浓缩物作为置换液成功进行术前凝血因子 VIII 抗体去除术。
J Clin Apher. 1986;3(2):140. doi: 10.1002/jca.2920030212.
引用本文的文献
1
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.意大利血友病及先天性出血性疾病的治疗原则与管理建议更新
Blood Transfus. 2014 Oct;12(4):575-98. doi: 10.2450/2014.0223-14.
本文引用的文献
1
Clinical and organisational aspects of haemophilia care: the patients' view.血友病护理的临床与组织方面：患者视角
Blood Transfus. 2012 Jan;10(1):110-1. doi: 10.2450/2011.0043-11. Epub 2011 Sep 21.
2
Haemophilia management: time to get personal?血友病管理：是否该个体化？
Haemophilia. 2011 Sep;17(5):721-8. doi: 10.1111/j.1365-2516.2011.02517.x. Epub 2011 Jun 8.
3
Factor VIII safety: plasma-derived versus recombinant products.凝血因子VIII的安全性：血浆源性产品与重组产品
Blood Transfus. 2011 Oct;9(4):366-70. doi: 10.2450/2011.0092-10. Epub 2011 Apr 12.
4
EUHASS: The European Haemophilia Safety Surveillance system.欧盟血友病安全监测系统。
Thromb Res. 2011 Jan;127 Suppl 2:S22-5. doi: 10.1016/S0049-3848(10)70150-X.
5
Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.用于治疗甲型血友病的血浆源性与重组凝血因子 VIII 浓缩剂：重组的更好。
Blood Transfus. 2010 Oct;8(4):292-6. doi: 10.2450/2010.0067-10.
6
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.用于治疗甲型血友病的血浆源性与重组凝血因子VIII浓缩剂：血浆源性的更好。
Blood Transfus. 2010 Oct;8(4):288-91. doi: 10.2450/2010.0072-10.
7
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.既往未接受治疗的血友病 A 患者接受血浆源性或重组因子 VIII 浓缩物治疗后抑制剂的发生率：系统评价。
J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17.
8
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8.
9
Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).凝血因子VIII产品与抑制剂的发展：SIPPET研究（血浆制品暴露幼儿中抑制剂的调查）
Haemophilia. 2007 Dec;13 Suppl 5:65-8. doi: 10.1111/j.1365-2516.2007.01580.x.
10
Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.基因疗法、生物工程凝血因子及血友病治疗的新技术。
J Thromb Haemost. 2007 May;5(5):901-6. doi: 10.1111/j.1538-7836.2007.02410.x.
Zotero 插件